Ernexa Therapeutics Inc.ERNANASDAQ
Loading
Net Income Growth TrendStable
Percentile Rank82
5Y CAGR+147.3%
Year-over-Year Change
Year-over-year net income growth rate
5Y CAGR
+147.3%/yr
Long-term compound
Percentile
P82
Within normal range
vs 5Y Ago
92.5x
Strong expansion
Streak
1 qtr
Consecutive declineStable
| Period | Value |
|---|---|
| Q3 2025 | 60.50% |
| Q2 2025 | 61.73% |
| Q1 2025 | -42.42% |
| Q4 2024 | 78.35% |
| Q3 2024 | -381.17% |
| Q2 2024 | 16.82% |
| Q1 2024 | -8.03% |
| Q4 2023 | -10.05% |
| Q3 2023 | -24.02% |
| Q2 2023 | 16.77% |
| Q1 2023 | -20.70% |
| Q4 2022 | 38.67% |
| Q3 2022 | -115.30% |
| Q2 2022 | 63.75% |
| Q1 2022 | -17.89% |
| Q4 2021 | 90.75% |
| Q3 2021 | -752.61% |
| Q2 2021 | 45.55% |
| Q1 2021 | -735.00% |
| Q4 2020 | -9.80% |
| Q3 2020 | 0.65% |
| Q2 2020 | -99.51% |
| Q1 2020 | 0.00% |